fbpx Skip to main content

IPO Pitfalls & Creative Funding Solutions for Life Sciences Companies

When:

August 15, 2019 11:30 amAugust 15, 2019 1:30 pm (PDT)

Where:

CEDARS-SINAI INNOVATION SPACE
8601 Beverly Boulevard
Los Angeles, 90048

Registration Closed

Join Biocom and CBIZ MHM for a lunch-and-learn discussing ways that CEOs and CFOs can avoid IPO pitfalls, and for those not looking to go public, how they can be both flexible and creative with the types of investors and investment arrangements they consider.

In this climate of an increasingly improved economy and a strengthening stock market, private companies looking to go public should be very wary. They should be aware of very significant pitfalls that lie in wait. Some biotech companies have raised tens and millions of dollars becoming publicly traded, while others have crashed and burned as a result of bad advice, poor handling, or choosing the wrong methodology to enter the public markets. Join us as we discuss more important steps to take in initiating the IPO process. For companies not yet pursuing the IPO option, larger public biotech companies are a significant source of capital. So, too, is venture capital, but not every biotech company will be able to connect with a blue-ship angel investor or venture capitalist that can address its capital needs, which could leave companies with funding challenges. Biotech CEOs will need to pursue multiple channels for capital to grow. The is to be both flexible and creative with the types of investor and investment arrangements considered.

Speakers:
Stuart Starr, Shareholder and Attest Practice Leader MHM (Mayer Hoffman McCann)
Stuart is an MHM Shareholder and Attest Practice Leader. He has over 25 years of experience in auditing and accounting. Stuart’s technical expertise is in providing audit and consulting services to life sciences and technology companies, investment funds, software developers, telecommunications service providers, manufacturers and distributors, both publicly traded and privately held, including many backed by venture capital. He has served as the audit partner on initial public offerings, as well as on innumerable other registration statement filings and ‘34 act filings. Stuart assists his clients with all types of significant accounting matters including revenue recognition, acquisition accounting, accounting for stock-based compensation, equity and debt instruments, and general business consulting enabling clients to make informed decisions on financial reporting matters.

Kelly O'Neil, Shareholder and Attest Practice Leader, MHM (Mayer Hoffman McCann)
Kelly is an MHM Shareholder and Attest Practice Leader. She has more than 20 years of experience. Kelly’s expertise is providing audit and consulting services to companies in the life sciences, technology, manufacturing and distribution, construction and real estate, and defense contractors for both public and large, privately-held companies (including many backed by private equity and venture capital firms).
She has a strong understanding of business processes and has been instrumental in developing solutions for corporate management on various accounting matters with significant focus on compliance, operations and internal control environments and the related financial statement impacts. Kelly assists her clients with revenue recognition, business combination and purchase accounting, accounting for stock-based compensation, equity and debt instruments, derivatives accounting, and general business consulting enabling clients to make informed decisions on financial reporting matters.



Sponsored By:
User-added image

User-added image

Price of Admission

Biocom Event

Today’s Price: 0

Important Dates

Amount

Registration before

Registration before

Registration before

Registration cost

0

Refund before 2019-08-15

0

Refund before

Refund Before

Registration Closed